Related references
Note: Only part of the references are listed.PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
PD-L1 expression and prognostic impact in glioblastoma
Edjah K. Nduom et al.
NEURO-ONCOLOGY (2016)
PDL1 Regulation by p53 via miR-34
Maria Angelica Cortez et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
IMMUNOTHERAPY PD-1 says goodbye, TIM-3 says hello
Diana Romero
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma
Zengjin Liu et al.
ONCOLOGY LETTERS (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Shohei Koyama et al.
NATURE COMMUNICATIONS (2016)
Anti-PD-L1 antibody active in metastatic bladder cancer
Vicki Brower
LANCET ONCOLOGY (2015)
Structural and functional features of central nervous system lymphatic vessels
Antoine Louveau et al.
NATURE (2015)
Enriched environment reduces glioma growth through immune and non-immune mechanisms in mice
Stefano Garofalo et al.
NATURE COMMUNICATIONS (2015)
Prognostic and predictive value of PDL1 expression in breast cancer
Renaud Sabatier et al.
ONCOTARGET (2015)
IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry
Pei Yang et al.
ONCOTARGET (2015)
PDL1 expression is an independent prognostic factor in localized GIST
Francois Bertucci et al.
ONCOIMMUNOLOGY (2015)
Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer
Jiabei He et al.
SCIENTIFIC REPORTS (2015)
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall- cell lung cancer
K. Azuma et al.
ANNALS OF ONCOLOGY (2014)
PD-L1 expression in nonclear-cell renal cell carcinoma
T. K. Choueiri et al.
ANNALS OF ONCOLOGY (2014)
circlize implements and enhances circular visualization in R
Zuguang Gu et al.
BIOINFORMATICS (2014)
PD1 (CD279) and PD-L1 (CD274, B7H1) expression in primary central nervous system lymphomas (PCNSL)
Anna Sophie Berghoff et al.
CLINICAL NEUROPATHOLOGY (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
GSVA: gene set variation analysis for microarray and RNA-Seq data
Sonja Haenzelmann et al.
BMC BIOINFORMATICS (2013)
Cell-based Immunotherapy Against Gliomas: From Bench to Bedside
M. Sarah S. Bovenberg et al.
MOLECULAR THERAPY (2013)
Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group
Wei Yan et al.
NEURO-ONCOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Correlation of IDH1 Mutation with Clinicopathologic Factors and Prognosis in Primary Glioblastoma: A Report of 118 Patients from China
Wei Yan et al.
PLOS ONE (2012)
Targeting PD-1/PD-L1 interactions for cancer immunotherapy
Laurence Zitvogel et al.
ONCOIMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
pROC: an open-source package for R and S plus to analyze and compare ROC curves
Xavier Robin et al.
BMC BIOINFORMATICS (2011)
Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma?
Amy B. Heimberger et al.
NEURO-ONCOLOGY (2011)
Exciting New Advances in Neuro-Oncology The Avenue to a Cure for Malignant Glioma
Erwin G. Van Meir et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
The stromal gene encoding the CD274 antigen as a genetic modifier controlling survival of mice with γ-radiation-induced T-cell lymphoblastic lymphomas
J. Santos et al.
ONCOGENE (2010)
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
Achim Rody et al.
BREAST CANCER RESEARCH (2009)
The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses
S. Farzana Hussain et al.
NEURO-ONCOLOGY (2006)
Share Paper
